JPWO2020165733A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020165733A5 JPWO2020165733A5 JP2021546382A JP2021546382A JPWO2020165733A5 JP WO2020165733 A5 JPWO2020165733 A5 JP WO2020165733A5 JP 2021546382 A JP2021546382 A JP 2021546382A JP 2021546382 A JP2021546382 A JP 2021546382A JP WO2020165733 A5 JPWO2020165733 A5 JP WO2020165733A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition
- amino
- therapeutic agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804707P | 2019-02-12 | 2019-02-12 | |
| US62/804,707 | 2019-02-12 | ||
| PCT/IB2020/051030 WO2020165733A1 (en) | 2019-02-12 | 2020-02-10 | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519385A JP2022519385A (ja) | 2022-03-23 |
| JPWO2020165733A5 true JPWO2020165733A5 (https=) | 2023-02-20 |
| JP2022519385A5 JP2022519385A5 (https=) | 2023-02-20 |
Family
ID=69724012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546382A Pending JP2022519385A (ja) | 2019-02-12 | 2020-02-10 | Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220160706A1 (https=) |
| EP (1) | EP3923940B1 (https=) |
| JP (1) | JP2022519385A (https=) |
| KR (1) | KR20210126652A (https=) |
| CN (1) | CN113395967A (https=) |
| AU (1) | AU2020222295B2 (https=) |
| BR (1) | BR112021015487A2 (https=) |
| CA (1) | CA3129031A1 (https=) |
| CL (1) | CL2021002100A1 (https=) |
| IL (1) | IL284837A (https=) |
| MX (1) | MX2021009562A (https=) |
| TW (1) | TW202045172A (https=) |
| WO (1) | WO2020165733A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112322A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
| JP2022502385A (ja) | 2018-09-29 | 2022-01-11 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物の製造方法 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| KR20210126653A (ko) * | 2019-02-12 | 2021-10-20 | 노파르티스 아게 | Tno155 및 리보시클립을 포함하는 약제학적 조합물 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| CN115916786B (zh) | 2020-07-08 | 2025-10-17 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| TW202241414A (zh) * | 2020-12-22 | 2022-11-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合以及ｋｒａｓ ｇ１２ｃ抑制劑用於治療癌症之用途 |
| IL308234A (en) | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Monotherapy with an SHP2 inhibitor and its uses |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CA3217084A1 (en) * | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| AU2016300208B2 (en) * | 2015-07-29 | 2019-08-08 | Novartis Ag | Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer |
| US20190343836A1 (en) * | 2017-01-10 | 2019-11-14 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| WO2020165732A1 (en) * | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| KR20210126653A (ko) * | 2019-02-12 | 2021-10-20 | 노파르티스 아게 | Tno155 및 리보시클립을 포함하는 약제학적 조합물 |
-
2020
- 2020-02-10 MX MX2021009562A patent/MX2021009562A/es unknown
- 2020-02-10 WO PCT/IB2020/051030 patent/WO2020165733A1/en not_active Ceased
- 2020-02-10 CN CN202080012523.1A patent/CN113395967A/zh active Pending
- 2020-02-10 AU AU2020222295A patent/AU2020222295B2/en active Active
- 2020-02-10 US US17/430,203 patent/US20220160706A1/en active Pending
- 2020-02-10 BR BR112021015487-6A patent/BR112021015487A2/pt not_active IP Right Cessation
- 2020-02-10 JP JP2021546382A patent/JP2022519385A/ja active Pending
- 2020-02-10 KR KR1020217028653A patent/KR20210126652A/ko not_active Ceased
- 2020-02-10 TW TW109104043A patent/TW202045172A/zh unknown
- 2020-02-10 EP EP20707826.2A patent/EP3923940B1/en active Active
- 2020-02-10 CA CA3129031A patent/CA3129031A1/en active Pending
-
2021
- 2021-07-13 IL IL284837A patent/IL284837A/en unknown
- 2021-08-10 CL CL2021002100A patent/CL2021002100A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020165733A5 (https=) | ||
| JPWO2020165734A5 (https=) | ||
| JPWO2020165732A5 (https=) | ||
| KR100793573B1 (ko) | 인체 기관의 평활근 세포의 수축에 의해 유발되는 건강질환의 예방 및 치료용 조성물을 위한 생화학 물질의 용도 | |
| NO972968L (no) | Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler | |
| IL300151A (en) | Combinations for cancer treatment | |
| WO2018068691A1 (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2024069192A5 (https=) | ||
| JP2025020117A5 (https=) | ||
| JP2021530502A5 (https=) | ||
| ME01335B (me) | Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura | |
| JP2022553175A (ja) | がんの処置における使用のためのα－メチル－ＤＬ－チロシンのアルキルエステル | |
| CA2920073A1 (en) | Boosting the effect of methotrexate through the combined use with lipophilic statins | |
| JPWO2021097220A5 (https=) | ||
| KR927002224A (ko) | 항종양효과증강제 및 항종양제 | |
| MX2025000142A (es) | Tratamiento con ciclobenzaprina para las secuelas postagudas de la infección por (sars)-cov-2 (pasc) | |
| IL320563A (en) | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases | |
| IL321302A (en) | Combined use of anilouracil and capecitabine for cancer treatment | |
| RU2021126525A (ru) | Фармацевтическая комбинация, содержащая tno155 и ингибитор pd-1 | |
| JPWO2022218956A5 (https=) | ||
| RU2021126526A (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| AU2002366975B2 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| US20240033238A1 (en) | Combination of compounds for use in therapy | |
| WO2024073328A3 (en) | Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer |